A registered nurse at the Altoona Center for Clinical Research in Duncansville, PA begins the process of preparing refrigerated doses of Pfizer's Lyme disease vaccine (Gary M. Baranec/AP Images)

February 23, 2023 10:47 AM ESTUpdated February 24, 05:37 PM

Pharma

Pfizer cuts CRO unicorn from Lyme vaccine trial in dispute over conduct

Drew Armstrong

Executive Editor

Kyle LaHucik

Senior Reporter

Pfizer is ending its work with research contractor Care Access on an 18,000-patient Lyme disease vaccine trial, according to an internal email reviewed by …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

TRENDING NOW

Pfizer cuts CRO unicorn from Lyme vaccine trial in dispute over conduct

Drew Armstrong

Executive Editor

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Pfiz­er cuts CRO uni­corn from Ly­me vac­cine tri­al in dis­pute over con­duct

Executive Editor

Senior Reporter

Sign up to read this article for free.

Pfizer cuts CRO unicorn from Lyme vaccine trial in dispute over conduct